Catalyst Pharmaceuticals Ownership | Who Owns Catalyst Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Catalyst Pharmaceuticals Ownership Summary


Catalyst Pharmaceuticals is owned by 69.08% institutional investors, 6.15% insiders, and 24.78% retail investors. Blackrock is the largest institutional shareholder, holding 16.01% of CPRX shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 5.73% of its assets in Catalyst Pharmaceuticals shares.

CPRX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCatalyst Pharmaceuticals69.08%6.15%24.78%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock18.69M16.01%$289.58M
Blackrock funding, inc. /de18.63M15.19%$434.75M
Vanguard group8.43M6.88%$196.81M
State street6.41M5.24%$126.19M
Deerfield management company, l.p. (series c)4.97M4.07%$98.00M
Fundsmith llp3.36M2.75%$66.27M
Dimensional fund advisors lp3.00M2.44%$69.93M
Morgan stanley2.93M2.39%$68.47M
Geode capital management2.90M2.37%$67.70M
Renaissance2.65M2.16%$61.85M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Gables capital management424.62K4.19%$9.91M
Tanaka capital management114.42K4.06%$2.25M
Jw asset management388.39K2.95%$9.07M
Knott david m jr189.00K2.04%$4.41M
Deerfield management company, l.p. (series c)4.97M1.50%$98.00M
Qsv equity investors36.01K1.24%$840.47K
Mesirow institutional investment management742.29K1.19%$15.49M
Bridge city capital156.68K1.07%$3.66M
Globeflex capital l p292.21K1.04%$6.82M
Pvg asset management11.79K0.72%$182.56K

Top Buyers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)4.97M1.50%2.10M
Morgan stanley2.93M0.00%1.09M
Blackrock18.69M0.01%962.28K
State street6.41M0.00%927.00K
American century companies2.53M0.03%770.20K

Top Sellers

HolderShares% AssetsChange
Renaissance2.65M0.10%-894.75K
Macquarie group---761.74K
Pacer advisors---620.80K
Point72 asset management---618.30K
Allianz asset management gmbh366.76K0.01%-431.19K

New Positions

HolderShares% AssetsChangeValue
Eversept partners, lp350.81K0.48%350.81K$6.91M
Tanaka capital management114.42K4.06%114.42K$2.25M
Empowered funds95.56K0.02%95.56K$2.23M
Norges bank91.77K0.00%91.77K$1.92M
Freestone grove partners lp60.74K0.01%60.74K$1.20M

Sold Out

HolderChange
Grey fox wealth advisors-1.00
Global financial private client-1.00
Jpl wealth management-5.00
Coppell advisory solutions-8.00
Mendota financial group-12.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025317-13.39%84,692,615-18.03%690.97%157-11.30%105-21.64%
Sep 30, 2025351-3.57%103,180,9191.77%841.23%169-19.52%1295.74%
Jun 30, 2025354-3.54%101,094,7563.01%821.27%2043.55%118-2.48%
Mar 31, 20253616.80%97,419,101-0.16%801.19%193-4.46%11933.71%
Dec 31, 20243294.44%99,023,9753.92%831.30%19521.88%87-17.14%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF6.99M5.73%-503.98K
Vanguard Total Stock Mkt Idx Inv3.68M3.01%10.79K
Vanguard US Total Market Shares ETF3.55M2.91%3.78K
Smithson Investment Trust Ord3.36M2.75%-
Avantis US Small Cap Value ETF3.16M2.59%18.00K
iShares Russell 2000 ETF2.78M2.27%631.87K
State Street® SPDR® S&P® Biotech ETF2.67M2.19%-14.31K
First Trust NYSE Arca Biotech ETF1.89M1.59%-
Vanguard Institutional Extnd Mkt Idx Tr1.25M1.02%2.76K
Fidelity Small Cap Index1.17M0.95%2.23K

Recent Insider Transactions


DateNameRoleActivityValue
Dec 12, 2025Harper Molly-Sell$155.56K
Dec 12, 2025Harper Molly-Sell$106.16K
Dec 12, 2025Harper Molly-Sell$360.20K
Nov 26, 2025Del Carmen Jeffrey Chief Commercial OfficerSell$256.24K
Nov 12, 2025Elsbernd Brian Chief Compliance/Legal OfficerBuy$908.00K

Insider Transactions Trends


DateBuySell
2026 Q1--
2025 Q4-5
2025 Q3-6
2025 Q2-7
2025 Q1-5

CPRX Ownership FAQ


Who Owns Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals shareholders are primarily institutional investors at 69.08%, followed by 6.15% insiders and 24.77% retail investors. The average institutional ownership in Catalyst Pharmaceuticals's industry, Biotech Stocks , is 381.47%, which Catalyst Pharmaceuticals falls below.

Who owns the most shares of Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals’s largest shareholders are Blackrock (18.69M shares, 16.01%), Blackrock funding, inc. /de (18.63M shares, 15.19%), and Vanguard group (8.43M shares, 6.88%). Together, they hold 38.08% of Catalyst Pharmaceuticals’s total shares outstanding.

Does Blackrock own Catalyst Pharmaceuticals?

Yes, BlackRock owns 16.01% of Catalyst Pharmaceuticals, totaling 18.69M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 289.58M$. In the last quarter, BlackRock increased its holdings by 962.28K shares, a 5.43% change.

Who is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Gables capital management is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 4.19% of its assets in 424.62K Catalyst Pharmaceuticals shares, valued at 9.91M$.

Who is the top mutual fund holder of Catalyst Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Catalyst Pharmaceuticals shares, with 5.73% of its total shares outstanding invested in 6.99M Catalyst Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools